Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study

Melanoma and Skin CancerImmunotherapy

Immunomodulatory effects of BRAF and MEK Inhibitors: Implications for Melanoma therapy

Pharmacol Res.

Kuske M, Westphal D, Wehner R, Schmitz M, Beissert S, Praetorius C, Meier F

doi: 10.1016/j.phrs.2018.08.019.

Melanoma and Skin Cancer

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

Eur J Cancer

Saiag P, Robert C, Grob JJ, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Dutriaux C

doi: 10.1016/j.ejca.2021.05.031

Melanoma and Skin Cancer

PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma

Melanoma Res

Marcaillou M, Linder C, Chaltiel L, Sibaud V, Pagès C, Modesto A, Chira C, Dalmasso C, Boulinguez S, Bedane C, Meyer N

doi: 10.1097/CMR.0000000000000700

Melanoma and Skin Cancer

Dermoscopy Improves the Diagnostic Accuracy of Melanomas Clinically Resembling Seborrheic Keratosis: Cross-Sectional Study of the Ability to Detect Seborrheic Keratosis-Like Melanomas by a Group of Dermatologists with Varying Degrees of Experience

Dermatology.

Carrera C, Segura S, Aguilera P, Takigami CM, Gomes A, Barreiro A, Scalvenzi M, Longo C, Cavicchini S, Thomas L, Malvehy J, Puig S, Zalaudek I

doi: 10.1159/000486851.

COMMENTED

Can Ultrasound Be Used to Predict Loss of Remission in Patients with RA in a Real-life Setting? A Multicenter Cohort Study

J Rheumatol.

Zufferey P, Scherer A, Nissen MJ, Ciurea A, Tamborrini G, Brulhart L, Blumhardt S, Toniolo M, Möller B, Ziswiler HR; SONAR Group and the SCQM Foundation

doi: 10.3899/jrheum.161193.

Melanoma and Skin Cancer

Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study

Eur J Cancer

Umeda Y, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Onuma T, Kuwatsuka Y, Fujimoto N, Kaneko T, Onishi M, Namikawa K, Yamazaki N, Nakamura Y

doi: 10.1016/j.ejca.2021.08.034

Melanoma and Skin Cancer

Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas

Melanoma Res

Holman BN, Van Gulick RJ, Amato CM, MacBeth ML, Davies KD, Aisner DL, Robinson WA, Couts KL

doi: 10.1097/CMR.0000000000000688

Melanoma and Skin Cancer

Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort

Br J Dermatol.

Del Regno L, Louveau B, Battistella M, Sadoux A, Baroudjian B, Delyon J, Serror K, Allayous C, Lebbe C, Mourah S, Jouenne F

doi: 10.1111/bjd.18641.

Psoriasis

A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic

J Eur Acad Dermatol Venereol

Hansel K, Zangrilli A, Bianchi L, Peris K, Chiricozzi A, Offidani A, Diotallevi F, Fargnoli MC, Esposito M, Amerio P, Gualdi G, Bianchi L, Stingeni L

doi: 10.1111/jdv.17003

Related content

Immunomodulatory effects of BRAF and MEK Inhibitors: Implications for Melanoma therapy

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma

Dermoscopy Improves the Diagnostic Accuracy of Melanomas Clinically Resembling Seborrheic Keratosis: Cross-Sectional Study of the Ability to Detect Seborrheic Keratosis-Like Melanomas by a Group of Dermatologists with Varying Degrees of Experience

Can Ultrasound Be Used to Predict Loss of Remission in Patients with RA in a Real-life Setting? A Multicenter Cohort Study

Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study

Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas

Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort

A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic